Related Experiment Video
Updated: Jun 9, 2026
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma
Yoshiaki Kita1, Koshi Mimori, Masaaki Iwatsuki
1Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan.
Annals of Surgical Oncology
|August 25, 2010
Summary
Stanniocalcin 2 (STC2) is overexpressed in esophageal cancer and linked to metastasis. STC2 may serve as a prognostic marker for esophageal cancer patients, impacting survival rates.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Esophageal squamous-cell cancer (ESCC) progression and metastasis involve complex genetic alterations.
- Identifying key genes is crucial for understanding ESCC pathogenesis and developing targeted therapies.
Purpose of the Study:
- To identify genes associated with the progression and metastasis of esophageal squamous-cell cancer.
- To investigate the role of stanniocalcin 2 (STC2) as a potential prognostic marker in ESCC.
Main Methods:
- Laser microdissection and oligo microarray analysis to compare gene expression profiles.
- Quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) and immunohistochemistry for STC2 validation.
- In vitro functional assays (transfection and RNA interference) to assess STC2's role in cell proliferation and invasion.
Main Results:
- Identified 63 candidate metastasis-related genes, with STC2 showing significantly higher expression in cancer tissues.
- STC2 expression correlated significantly with lymph node metastasis, lymphatic invasion, and distant metastasis.
- High STC2 expression was associated with poorer 5-year survival rates and increased cancer cell proliferation and invasion.
Conclusions:
- STC2 is a lymph node-specific, metastasis-related gene in esophageal cancer.
- STC2 may serve as a valuable prognostic biomarker for predicting outcomes in esophageal cancer patients.
